45 results
424B3
SYRE
Spyre Therapeutics Inc.
15 May 24
Prospectus supplement
4:06pm
developed by us and our research partners at Paragon. Prior to the closing of the Asset Acquisition, Paragon had sole leadership in conducting in vitro
8-K
EX-99.1
SYRE
Spyre Therapeutics Inc.
15 May 24
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
7:40am
career spanning leadership roles at large and small biopharmaceutical companies, Dr. Milligan brings deep expertise in clinical development and regulatory
8-K
EX-99.1
SYRE
Spyre Therapeutics Inc.
9 May 24
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:11pm
of corporate leadership, product development, and value creation will be instrumental to guide the Company as it advances its potentially best-in-class
POS AM
wxisze56dfq
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
POS AM
ogbfovtez hj566j6e5v
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
POS AM
lzu48btongu0ab 5mxu
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
8-K
EX-99.1
aifs jyz7clo6ch0
29 Feb 24
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:14pm
424B3
gxkr7peao4u
30 Nov 23
Prospectus supplement
5:18pm
8-K
EX-99.1
lexww8gz 9w9e
28 Nov 23
Appoints CEO and Additional Directors, and Expands Leadership Team to
7:33am
8-K
EX-99.1
vsp8j43x5p37
9 Nov 23
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:06pm
8-K
EX-99.1
119hutvla9n3lbf1
24 Oct 23
Regulation FD Disclosure
9:00am